<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02779075</url>
  </required_header>
  <id_info>
    <org_study_id>16-001973</org_study_id>
    <nct_id>NCT02779075</nct_id>
  </id_info>
  <brief_title>Exendin-9,39 and Satiety After Bariatric Surgery</brief_title>
  <official_title>Exendin-9,39 and Satiety After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Obesity Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of the application is to determine the contribution of the elevated incretin
      hormone concentrations seen after certain types of bariatric surgery to the regulation of
      food intake and satiety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both Sleeve Gastrectomy (SG) and Roux-en-Y Gastric Bypass (RYGB) increase GLP-1
      concentrations, although this is of lesser magnitude in SG compared to RYGB. Data suggests
      that endogenous GLP-1 is at least partially responsible for reducing free-choice caloric
      intake after RYGB, providing a mechanism underlying differences between procedures.
      Inhibition of GLP-1 action with Exendin-9,39 after RYGB accelerates gastric emptying. These
      observations suggest that factors other than anatomy regulate the upper gastrointestinal
      response to food ingestion. It is therefore reasonable to consider that the postprandial rise
      in GLP-1 might affect feeding behavior after RYGB, and to a lesser extent SG, where the
      increase in GLP-1 is less marked.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Caloric Intake</measure>
    <time_frame>5 hours</time_frame>
    <description>caloric intake from a free choice buffet within 5 hours after ingestion of a standard meal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal transit measured using scintigraphy</measure>
    <time_frame>4 hours</time_frame>
    <description>measured using scintigraphy over the 4 hours after ingestion of a labeled meal</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% NaCL (saline) intravenously for 6 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin-9,39</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exendin-9,39 intravenously for 6 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Subjects will be studied on 2 occasions, in random order. During the saline study they will be infused with saline.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin-9,39</intervention_name>
    <description>Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.</description>
    <arm_group_label>Exendin-9,39</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergone either sleeve gastrectomy or Roux-en-Y Gastric Bypass surgery within prior 2
             years

          -  Healthy, with no active systemic illness

        Exclusion Criteria:

          -  Pregnancy

          -  Functional or organic bowel symptoms

          -  Systemic illness

          -  Diabetes

          -  Bariatric surgery &gt; 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Vella</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula D Giesler, RN, BSN, CDE</last_name>
    <phone>507-255-8345</phone>
    <email>giesler.paula@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>May 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2016</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Adrian Vella</investigator_full_name>
    <investigator_title>MD, FRCP (Edin), Consultant Division or Endocrinolgy, Diabetes and Nutrition</investigator_title>
  </responsible_party>
  <keyword>Sleeve Gastrectomy</keyword>
  <keyword>Roux-en-Y Gastric Bypass</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

